Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Xinxin Cao, Na Niu, Jian Sun, Hao Cai, Feng-dan Wang, Yi-ning Wang, Ding-rong Zhong, Ming-hui Duan, MD, Dao-bin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2018-99-114040

Published: 2018

Journal Articles

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Blood (2018) 132 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2018-99-116844

Published: 2018

Journal Articles

Peritransplant Complications and Long-Term Outcomes of Patients with Newly Diagnosed POEMS Syndrome after Upfront Autologous Stem Cell Transplantation

Jian Li, MD, Ming-hui Duan, MD, Wei Zhang, MD, Chen Wang, MD, Xu-fei Huang, MD, Tie-nan Zhu, MD, Hua-cong Cai, MD, Xin-xin Cao, MD, Dao-bin Zhou, MD

Blood (2016) 128 (22): 2259.

https://doi.org/10.1182/blood.V128.22.2259.2259

Published: 2016

Journal Articles

Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

Xin-xin Cao, MD, Jian Sun, MD, Jian Li, MD, Ding-rong Zhong, MD, Na Niu, Bachelor, Ming-hui Duan, MD, Zhi-yong Liang, MD, Dao-bin Zhou, MD

Blood (2015) 126 (23): 3870.

https://doi.org/10.1182/blood.V126.23.3870.3870

Published: 2015

Journal Articles

A Paracrine Circuit Regulates Vascular Endothelial Growth Factor Production By Bone Marrow Plasma Cells in Patients with POEMS Syndrome

Chen Wang, MD, Qian-qian Cai, MD, Xin-xin Cao, MD, Dao-bin Zhou, MD, Jian Li, MD

Blood (2015) 126 (23): 1757.

https://doi.org/10.1182/blood.V126.23.1757.1757

Published: 2015

Journal Articles

A Prospective Phase II Study of Combination of Low Dose Lenalidomide and Dexamethasone for Patients with Newly Diagnosed POEMS Syndrome

Jian Li, MD, Qian-qian Cai, MD, Chen Wang, MD, Xin-xin Cao, MD, Dao-bin Zhou, MD

Blood (2015) 126 (23): 192.

https://doi.org/10.1182/blood.V126.23.192.192

Published: 2015

Journal Articles

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiaoyan Ke, MD PhD, Xiao Li, MD PhD, Depei Wu, MD, Fanyi Meng, MD, Dena DeMarco, Jingshan Zhang, PhD, Jay Mei, MD, Jian Hou, MD PhD

Blood (2014) 124 (21): 5737.

https://doi.org/10.1182/blood.V124.21.5737.5737

Published: 2014

Journal Articles

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Jie Jin, MD, Xin Du, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jianmin Wang, MD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 3227.

https://doi.org/10.1182/blood.V122.21.3227.3227

Published: 2013

Journal Articles

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

Dao-bin Zhou, MD, Li Yu, MD, Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jianmin Wang, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 5374.

https://doi.org/10.1182/blood.V122.21.5374.5374

Published: 2013

Journal Articles

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Jian Hou, MD, PhD, Jie Jin, MD, Zhen Cai, Fangping Chen, Li Yu, Dao-bin Zhou, MD, Xiao Li, MD, PhD, Xiaoyan Ke, MD, PhD, Depei Wu, MD, Huisheng Ai, Fanyi Meng, MD, Jianmin Wang, Jay Mei, MD, PhD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Xin Du, PhD

Blood (2012) 120 (21): 1864.

https://doi.org/10.1182/blood.V120.21.1864.1864

Published: 2012

Journal Articles

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Nianhang Chen, PhD, Dao-bin Zhou, MD, Li Yu, Jay Mei, MD, PhD, Liangang Liu, Xiaomin Wang, Honeylet Wortman-Vayn, Jian Hou, MD, PhD

Blood (2012) 120 (21): 5046.

https://doi.org/10.1182/blood.V120.21.5046.5046

Published: 2012

NARROW

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Peritransplant Complications and Long-Term Outcomes of Patients with Newly Diagnosed POEMS Syndrome after Upfront Autologous Stem Cell Transplantation

Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

A Paracrine Circuit Regulates Vascular Endothelial Growth Factor Production By Bone Marrow Plasma Cells in Patients with POEMS Syndrome

A Prospective Phase II Study of Combination of Low Dose Lenalidomide and Dexamethasone for Patients with Newly Diagnosed POEMS Syndrome

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only